Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. Feb. 20, 2019. Karl Vahey.

Executive Summary

When a device-maker is trying to figure out what went wrong with a troublesome product, launching a failure investigation is a must. But a firm can find itself in hot water quickly if it kicks off the investigation with a weak or incorrect problem statement, Cardinal Health's Karl Vahey says.

"If you don’t have an accurate problem statement, you’re going to be going after the wrong thing and ultimately implement a corrective action that is not applicable to the problem that you have." –Karl Vahey, VP of Operations Quality, Cardinal Health Inc.

Click here for a free trial of Medtech Insight

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel